(CNTG) Centogene V - Ratings and Ratios
Exchange: NASDAQ • Country: Germany • Currency: USD • Type: Common Stock • ISIN: NL0014040206
CNTG: Diagnostic Tests, Genetic Sequencing, Data Analysis Software, Genetic Interpretation Tools
Centogene N.V. (NASDAQ:CNTG) is a global leader in the field of rare and neurodegenerative diseases, offering a comprehensive suite of pharmaceutical solutions and diagnostic tests. With operations spanning Europe, the Middle East, North America, Latin America, and the Asia Pacific, the company delivers data-driven insights to patients, physicians, and pharmaceutical companies. Its cutting-edge solutions include CENTOGENE MOx 2.0, a multiomic testing platform that integrates DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based SaaS platform designed for genomic variant analysis; FilterTool, a genetic data interpretation tool; and CentoGenome, an NGS-based assay for diagnostic insights. Additionally, the company provides services such as target and drug screening, clinical development, market access, and patient recruitment, alongside its proprietary CENTOGENE Biodatabank for biomarker discovery and epidemiological research. Founded in 2006 and headquartered in Rostock, Germany, Centogene has established itself as a pioneer in genetic sequencing and diagnostics, offering whole exome, whole genome, and multiomic testing solutions to healthcare providers worldwide.
Based on the provided data, here is a 3-month forecast:
3-Month Forecast: The stock is expected to remain range-bound with limited upside potential due to low trading volume and volatility. The SMA 200 at 0.21 represents a potential resistance level, while the SMA 20 and SMA 50 suggest near-term stability. With a low ATR of 0.01, price fluctuations are likely to remain minimal. On the fundamental side, the low P/S ratio of 0.19 and P/B ratio of 0.86 indicate undervaluation, but the lack of P/E and forward P/E suggests earnings uncertainty. The high RoE of 96.73% may reflect leverage or operational efficiency, but without additional context, it remains a neutral factor. Overall, the stock is likely to trade sideways with potential for slight downward pressure due to its small market cap and limited liquidity.
Additional Sources for CNTG Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CNTG Stock Overview
Market Cap in USD | 9m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2019-11-07 |
CNTG Stock Ratings
Growth 5y | -95.4% |
Fundamental | -7.11% |
Dividend | 0.0% |
Rel. Strength Industry | -78.6 |
Analysts | 4/5 |
Fair Price Momentum | 0.06 USD |
Fair Price DCF | - |
CNTG Dividends
No Dividends PaidCNTG Growth Ratios
Growth Correlation 3m | 68.7% |
Growth Correlation 12m | -81.1% |
Growth Correlation 5y | -95.7% |
CAGR 5y | -59.75% |
CAGR/Max DD 5y | -0.60 |
Sharpe Ratio 12m | -0.01 |
Alpha | -82.36 |
Beta | -0.04 |
Volatility | 106.20% |
Current Volume | 4.3k |
Average Volume 20d | 3.6k |
As of March 15, 2025, the stock is trading at USD 0.15 with a total of 4,343 shares traded.
Over the past week, the price has changed by +7.09%, over one month by +16.23%, over three months by +25.92% and over the past year by -78.39%.
Neither. Based on ValueRay Fundamental Analyses, Centogene V is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -7.11 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CNTG as of March 2025 is 0.06. This means that CNTG is currently overvalued and has a potential downside of -60%.
Centogene V has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy CNTG.
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CNTG Centogene V will be worth about 0.1 in March 2026. The stock is currently trading at 0.15. This means that the stock has a potential downside of -46.67%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 1.5 | 913.3% |
Analysts Target Price | 1.5 | 906.7% |
ValueRay Target Price | 0.1 | -46.7% |